AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
176.01
+0.12 (+0.07%)
At close: 4:00PM EDT

176.01 0.00 (0.00%)
After hours: 5:15PM EDT

Stock chart is not supported by your current browser
Previous Close175.89
Open176.43
Bid175.61 x 1800
Ask177.75 x 1100
Day's Range175.52 - 176.77
52 Week Range166.30 - 210.19
Volume2,081,791
Avg. Volume2,821,487
Market Cap107.355B
Beta (3Y Monthly)0.95
PE Ratio (TTM)14.04
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield5.80 (3.30%)
Ex-Dividend Date2019-05-16
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire5 days ago

    Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States

    THOUSAND OAKS, Calif., July 18, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).

  • PR Newswire13 days ago

    Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention

    THOUSAND OAKS, Calif., July 11, 2019 /PRNewswire/ -- Amgen (AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program. The Generation Program was designed to research the safety and efficacy of CNP520 for the prevention or delay of the onset of Alzheimer's disease in people at high risk for developing symptoms based on age and their genetic status. Alzheimer's is a complex disease and one of the largest challenges facing healthcare today.

  • PR Newswire16 days ago

    Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer

    The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in the United States should refer to the section entitled "Important Information to U.S. Shareholders" at the end of this press release.

  • PR Newswire26 days ago

    Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU

    THOUSAND OAKS, Calif. and BRUSSELS, June 27, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application for EVENITYTM (romosozumab) for the treatment of severe osteoporosis. "After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year,1 and these fractures can be life-changing.

  • PR Newswire29 days ago

    Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket

    SAN FRANCISCO, June 25, 2019 /PRNewswire/ -- Amgen (AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance their scientific programs. Amgen has been sponsoring MBC BioLabs since 2016 to assist high-potential and innovative early-stage life science and biotech companies in their efforts to accelerate the development of new therapies to improve human health.

  • PR Newswirelast month

    Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

    THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. Under the terms of the agreement, Amgen has provided initial funding for three sponsored research projects that will seek to apply IPD's de novo design technique to increase the versatility of traditional protein-based medicines. This will include optimizing Amgen's repertoire of BiTE® (bispecific T cell enager) antibodies, with the goal of expanding the types of tumors that can be targeted with these molecules.

  • PR Newswirelast month

    Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

    Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia More Than Half of Patients who Achieved an MRD-Negative ...

  • PR Newswirelast month

    FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

    THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

  • PR Newswirelast month

    Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution

    The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. On 22 May 2019 at 08:00 CEST, Amgen Inc. ("Amgen") (AMGN) announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer") for SEK 32.50 per share in cash (the "Offer Price").(1) Nuevolution's shares are listed on Nasdaq Stockholm, Small Cap.

  • PR Newswire2 months ago

    Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    THOUSAND OAKS, Calif. , June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40 th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday , June 12, 2019, in Rancho ...

  • Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019
    CNW Group2 months ago

    Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019

    MISSISSAUGA, ON , June 5, 2019 /CNW/ - Amgen (AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose levels.

  • Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
    CNW Group2 months ago

    Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019

    MISSISSAUGA, ON , June 5, 2019 /CNW/ - Amgen (AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago . Data presented included updated investigational AMG 420 results in patients with relapsed and/or refractory multiple myeloma (R/R MM), as well as initial results from the investigational AMG 212 (pasotuxizumab) first-in-human trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • PR Newswire2 months ago

    Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019

    THOUSAND OAKS, Calif., June 3, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose levels. "KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago, but it remained undruggable due to a lack of traditional small molecule binding pockets on the protein.

  • PR Newswire2 months ago

    Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

    THOUSAND OAKS, Calif., June 2, 2019 /PRNewswire/ -- Amgen (AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Data presented included updated investigational AMG 420 safety and efficacy results in patients with relapsed and/or refractory multiple myeloma (R/R MM), as well as initial results from the investigational AMG 212 (pasotuxizumab) first-in-human trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • PR Newswire2 months ago

    Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

    THOUSAND OAKS, Calif. , May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT . David M. Reese , M.D., executive vice president ...

  • PR Newswire2 months ago

    Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution

    The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. On 22 May 2019 at 08:00 CEST, Amgen Inc. ("Amgen") (AMGN) announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer") for SEK 32.50 per share in cash (the "Offer Price").(1) Nuevolution's shares are listed on Nasdaq Stockholm, Small Cap.

  • PR Newswire2 months ago

    Amgen Joins With Community Oncology Networks For New Research Collaboration

    THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ -- Amgen (AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiative to enhance access by community centers to innovative oncology clinical research. Fewer than one in 20 adult cancer patients in the U.S. have participated in a clinical trial.1 The collaboration will allow Amgen to significantly expand its clinical research footprint to more than 200 patient care sites across the U.S. and help community centers reach more than 900,000 new patients each year with investigational medicines.

  • PR Newswire2 months ago

    Amgen announces a recommended public cash offer to the shareholders of Nuevolution

    The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in the United States should refer to the section entitled "Important Information to U.S. Shareholders" at the end of this press release. Amgen Inc. ("Amgen") (AMGN) today announces a recommended public cash offer to the shareholders of Nuevolution AB (publ) ("Nuevolution") to tender all their shares in Nuevolution to Amgen (the "Offer").

  • PR Newswire2 months ago

    Amgen Announces Voting Results Of Annual Meeting Of Stockholders

    THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors.

  • PR Newswire2 months ago

    Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference

    THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

  • PR Newswire2 months ago

    Amgen Showcases Oncology Pipeline At ASCO 2019

    THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. "Biology and human genetics have been the foundation of Amgen's innovation for the last four decades," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • PR Newswire2 months ago

    Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference

    THOUSAND OAKS, Calif. , May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019 . David W. ...

  • PR Newswire3 months ago

    Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting

    THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe) across the migraine spectrum at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia. Data from a one-year open-label extension (OLE) trial following a three-month double blind study in patients with chronic migraine (15 or more headache days per month) showed sustained efficacy and safety in this patient population, including a potential for conversion to episodic migraine (4-14 headache days a month).

  • PR Newswire3 months ago

    Amgen And Syapse Enter Precision Medicine Collaboration In Oncology

    THOUSAND OAKS, Calif. and SAN FRANCISCO, May 2, 2019 /PRNewswire/ -- Amgen (AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology. This effort will identify existing patients within the Syapse Learning Health Network that could be eligible for Amgen-sponsored clinical trials and seek to bring these trials to community health system sites.

  • PR Newswire3 months ago

    Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer

    THOUSAND OAKS, Calif., May 1, 2019 /PRNewswire/ -- Amgen (AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's Breakaway Challenge joins together Breakaway from Cancer® and Breakaway from Heart Disease™ and serves as a complementary component to its title sponsorship of the Amgen Tour of California, a world-class cycling event that takes place May 12 – 18, 2019.